Hot on the trail of companion diagnostics partnerships, Qiagen is teaming up with pharma bigwig Novartis to develop tests for the company's drug portfolio.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.
Amid growing demand for portable, low-cost diagnostics, Indian startup Swasthya Slate is developing a device that could help reduce costs and improve outcomes for patients in developing countries.
As the diagnostics industry explores innovative ways to monitor and contain bacterial infections, Illumina is joining forces with French diagnostic outfit bioMérieux to develop a next-generation sequencing system that can identify infectious bacteria in service labs and hospitals.
Illumina is lending a hand to Ebola diagnostic efforts, teaming up with U.S. government officials and researchers at the Broad Institute to help scientists in West Africa track the virus and develop new tools to prevent its spread.
Coming off a huge third quarter for revenue growth, genomic sequencing outfit Illumina this week inked a deal with Sequenta to commercialize a diagnostics kit that detects a condition associated with cancer remission.
From Our Sister Sites
A U.K. consortium led by Zoetis announced a $3 million project that will use visual imaging and digital technology to improve the health and wellness of pig herds with a goal of better production.
Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects.